How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
2-valent HPV Vaccine (2vHPV) Market
- By End User: Hospitals, Clinics, Specialty Centers, Public Health Programs, Pharmacies
- By Age Group: Adolescents (9-14 years), Young Adults (15-26 years), Adults (27-45 years), Older Adults (46 years and above)
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Government Immunization Programs
- By Vaccination Indication: Primary Prevention, Catch-up Vaccination, Therapeutic Use
- By Dosage Schedule: Two-dose Schedule, Three-dose Schedule
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hospitals leads By End User at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the 2-valent HPV Vaccine (2vHPV) Market report
A complete, evidence-based study - 12 chapters and 116 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
End User 5
Age Group 4
Distribution Channel 4
Vaccination Indication 3
Dosage Schedule 2
Companies profiled
GlaxoSmithKline (GSK)
Merck & Co.
Inc. (MSD)
Sanofi Pasteur
Serum Institute of India
Bharat Biotech
Walvax Biotechnology
Shanghai Zerun Biotechnology
Innovax
Xiamen Innovax Biotech
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →GlaxoSmithKline (GSK)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Merck & Co.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Inc. (MSD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sanofi Pasteur
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Serum Institute of India
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Bharat Biotech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Walvax Biotechnology
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Shanghai Zerun Biotechnology
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Innovax
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Xiamen Innovax Biotech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,125M by 2033 · 4.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hospitals49.6
- Clinics15.6
- Specialty Centers6.9
- Public Health Programs15.0
- Pharmacies12.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$714.7M → $941.8M · 3.5%
Europe$498.1M → $761.8M · 5.5%
Asia Pacific$454.8M → $666.9M · 4.9%
Latin America$281.5M → $383.8M · 4.0%
Middle East and Africa$216.6M → $352.0M · 6.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.642026
4.662027
4.662028
4.682029
4.702030
4.712031
4.712032
4.722033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- GlaxoSmithKline (GSK)14.6
- Merck & Co.22.1
- Inc. (MSD)6.5
- Sanofi Pasteur4.4
- Serum Institute of India14.2
- Bharat Biotech10.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →End User14.0%
Age Group24.5%
Distribution Channel24.1%
Vaccination Indication15.4%
Dosage Schedule22.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.3
- Europe24.5
- Asia Pacific21.5
- Latin America12.4
- Middle East and Africa11.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| GlaxoSmithKline (GSK) | 76 | 84 | 82 | 80 | 94 | 80 | 83 |
| Merck & Co. | 84 | 88 | 75 | 77 | 77 | 91 | 82 |
| Inc. (MSD) | 84 | 67 | 75 | 77 | 81 | 85 | 78 |
| Sanofi Pasteur | 61 | 60 | 64 | 72 | 74 | 60 | 65 |
| Serum Institute of India | 77 | 61 | 69 | 61 | 69 | 57 | 66 |
| Bharat Biotech | 59 | 61 | 66 | 64 | 48 | 56 | 59 |
| Walvax Biotechnology | 62 | 44 | 44 | 48 | 49 | 53 | 50 |
| Shanghai Zerun Biotechnology | 53 | 41 | 49 | 51 | 45 | 37 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- GlaxoSmithKline (GSK)
- Merck & Co.
- Inc. (MSD)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| GlaxoSmithKline (GSK) | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Merck & Co. | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Inc. (MSD) | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Sanofi Pasteur | ◐ | ◐ | ✓ | ◐ | ✓ | − |
| Serum Institute of India | ✓ | ◐ | − | ◐ | − | ◐ |
| Bharat Biotech | ◐ | ◐ | − | ◐ | − | − |
| Walvax Biotechnology | − | − | ◐ | − | − | − |
| Shanghai Zerun Biotechnology | ◐ | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1GlaxoSmithKline (GSK)83
2Merck & Co.82
3Inc. (MSD)78
4Serum Institute of India66
5Sanofi Pasteur65
6Bharat Biotech59
7Walvax Biotechnology50
8Shanghai Zerun Biotechnology46
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
GlaxoSmithKline (GSK)Merck & Co.Inc. (MSD)
Contender3
Focused players with pockets of strength.
Sanofi PasteurSerum Institute of IndiaBharat Biotech
Niche2
Specialists in a single segment or region.
Walvax BiotechnologyShanghai Zerun Biotechnology
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land End User in North America, then scale across 2-valent HPV Vaccine (2vHPV) Market — a $364M beachhead inside a $7.15B market.
Beachhead (SOM)$364Mobtainable near-term
Serviceable (SAM)$2.47Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Hospitals
Best fit — highest urgency & budget in End User.
Economic buyer81 fit
Clinics
Strong fit — clear ROI and a fast path to value.
End user69 fit
Specialty Centers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win End User in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Age Group & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Distribution Channel
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For End User leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win 2-valent HPV Vaccine (2vHPV) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified25%
Evaluation14%
Closed-won8%
$12.0KCAC
$62KLTV
5.2:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
2-valent HPV Vaccine (2vHPV) Market is a high-growth opportunity — $3.84B by 2033, compounding at 11.3%.
TAM · 2025$1.63Btoday
TAM · 2033$3.84Bforecast
CAGR11.3%2027–2033
Cumulative$23.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.84BTotal addressable market
SAM$1.54BServiceable available market
SOM$250MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.3% CAGR
Demand compounds through 2033, outpacing GDP across End User.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in End User moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.84BLarge & growingTAM by 2033 at 11.3% CAGR
$1.54BServiceable nowreachable with today’s model
$250MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.99BBear7.4% CAGR
$3.84BBase11.3% CAGR
$4.91BBull15.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Age Group optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
2-valent HPV Vaccine (2vHPV) Market — a $5.33B market by 2033. Plan: grow share from 9.6% to 18.1%.
Market size · 2033$5.33Btotal addressable
Market CAGR4.0%2027–2033
Target share18.1%from 9.6% today
Revenue ambition$964Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.6% | 18.1% | On track |
| Revenue | $501M | $964M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 32.4% | 39.6% | At risk |
| Customer retention | 86.1% | 94.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in End User
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Age Group capability
A defensible second engine — invest in Age Group to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core End User share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Age Group
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $116M capacity & capability investment
- Greenlight bolt-on M&A in Age Group
- Authorise North America expansion plan
- Fund R&D program for End User leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the 2-valent HPV Vaccine (2vHPV) Market conversation — a $3.83B market you can size, segment and defend in minutes.
Market size · 2033$3.83Btotal opportunity
Growth10.1%CAGR to 2033
Addressable buyers1,328+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of End User
Goal Grow share in End User
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 4 mopayback period
$41K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
GlaxoSmithKline (GSK)Merck & Co.Inc. (MSD)Sanofi PasteurSerum Institute of IndiaBharat BiotechWalvax BiotechnologyShanghai Zerun Biotechnology+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your 2-valent HPV Vaccine (2vHPV) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
2-valent HPV Vaccine (2vHPV) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →2-Thiouracil Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportMedical Inventory Software Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportAnti Adhesion Products Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View report2-Station Surgical Sink Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View report2'-OMe-Ibu-G Phosphoramidite Market
Market size, share, segmentation and regional forecast.
$384M market · 2025 base year
View report2-Octyl Cyanoacrylate Skin Adhesive Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View report2-Isothiourea N-oxide Hydrochloride Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View report2'-Fucosyllactose (2'-FL) Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View report2-Fluorophenylhydrazine Hydrochloride Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View report2-Fluoro-d-phenylalanine Market
Market size, share, segmentation and regional forecast.
$371M market · 2025 base year
View report2D Mobile C-Arm Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View report2D Mammography System Market
Market size, share, segmentation and regional forecast.
$453M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.